SUBSCRIBE
SUBSCRIBE

Novartis Gene Therapies

NEWS
Man hiding under laptop
Drug Development
Does Novartis’ Acquisition of AveXis Spell Trouble for Biogen?
Switzerland-based Novartis is buying Bannockburn, Illinois-based AveXis for $8.7 billion. This could spell big trouble for Cambridge, Massachusetts-based Biogen.
April 10, 2018
 · 
3 min read
 · 
Mark Terry
File folder with Merger and Acquisition and financial graphs. Business concept
Deals
In Second Gene Therapy Buy of the Year, Novartis Acquires AveXis for $8.7B
Novartis has struck a deal to acquire AveXis for $8.7 billion. Novartis will pay $218 per share, which is a 72 percent premium over AveXis’s 30-day volume-weighted average stock price.
April 9, 2018
 · 
3 min read
 · 
Mark
Gemini Therapeutics Banks $42.5M to Bring Precisio
BioMidwest
These 3 Gene Therapy Biotechs Could Make Investors Rich
Immuno-oncology and gene therapy has been a hot field for the last few years, and the approval of the first CAR-T therapies has only set the kindling ablaze.
October 23, 2017
 · 
3 min read
 · 
Mark Terry
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Bio NC
Top 5 Biotech Winners and Losers of Q1 2016
March 31, 2016
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
With Ex-InterMune Exec at Its Helm, AveXis Scores $65 Million
September 8, 2015
 · 
2 min read
Load More
AWARDS
  • 2023 Best Places to Work
JOBS
IN THE PRESS
Bio NC
Health Alert for Parents: How one boy is thriving following treatment with a gene therapy after receiving an early diagnosis
October 12, 2022
 · 
7 min read
Policy
Novartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma® the only gene therapy for patients with spinal muscular atrophy (SMA)
June 22, 2020
 · 
11 min read
AveXis presents AVXS-101 IT data demonstrating remarkable increases in HFMSE scores and a consistent clinically meaningful response in older patients with SMA Type 2
June 22, 2020
 · 
14 min read
Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing
June 22, 2020
 · 
21 min read
AveXis receives positive CHMP opinion for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)
June 22, 2020
 · 
14 min read
Policy
AveXis receives EC approval and activates “Day One” access program for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)
June 22, 2020
 · 
14 min read
Business
Catalent Biologics Announces Agreement to Provide Additional Production of Approved Gene Therapy Treatment for Spinal Muscular Atrophy
October 31, 2019
 · 
4 min read
Drug Development
AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
September 19, 2019
 · 
18 min read
BIA Separations Selected for Manufacturing Process Development Support for Gene Therapy Pipeline
July 22, 2019
 · 
2 min read
AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families
May 24, 2019
 · 
19 min read
Load More